NPs Basic Information
|
Name |
3-oxogitoxigenin
|
| Molecular Formula | C23H32O5 | |
| IUPAC Name* |
3-(14,16-dihydroxy-10,13-dimethyl-3-oxo-2,4,5,6,7,8,9,11,12,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl)-2H-furan-5-one
|
|
| SMILES |
CC12CCC(=O)CC1CCC1C2CCC2(C)C(C3=CC(=O)OC3)C(O)CC12O
|
|
| InChI |
InChI=1S/C23H32O5/c1-21-7-5-15(24)10-14(21)3-4-17-16(21)6-8-22(2)20(13-9-19(26)28-12-13)18(25)11-23(17,22)27/h9,14,16-18,20,25,27H,3-8,10-12H2,1-2H3/t14-,16+,17-,18+,20+,21+,22-,23+/m1/s1
|
|
| InChIKey |
IVNCBFFQBDZLBF-YIDVOGGQSA-N
|
|
| Synonyms |
NA
|
|
| CAS | NA | |
| PubChem CID | NA | |
| ChEMBL ID | NA |
*Note: the IUPAC Name was calculated by STOUT. Reference: PMID:33906675.
Chemical Classification: |
|
|
|---|
——————————————————————————————————————————
NPs Species Source
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
|---|---|---|---|---|---|---|---|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
NPs Biological Activity
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
NPs Physi-Chem Properties
| Molecular Weight: | 388.5 | ALogp: | 2.8 |
| HBD: | 2 | HBA: | 5 |
| Rotatable Bonds: | 1 | Lipinski's rule of five: | Accepted |
| Polar Surface Area: | 83.8 | Aromatic Rings: | 5 |
| Heavy Atoms: | 28 | QED Weighted: | 0.671 |
——————————————————————————————————————————
NPs ADMET Properties*
ADMET: Absorption
| Caco-2 Permeability: | -5.003 | MDCK Permeability: | 0.00002510 |
| Pgp-inhibitor: | 0.004 | Pgp-substrate: | 0.013 |
| Human Intestinal Absorption (HIA): | 0.585 | 20% Bioavailability (F20%): | 0.705 |
| 30% Bioavailability (F30%): | 0.678 |
——————————————————————————————————————————
ADMET: Distribution
| Blood-Brain-Barrier Penetration (BBB): | 0.956 | Plasma Protein Binding (PPB): | 92.46% |
| Volume Distribution (VD): | 1.244 | Fu: | 7.29% |
——————————————————————————————————————————
ADMET: Metabolism
| CYP1A2-inhibitor: | 0.018 | CYP1A2-substrate: | 0.792 |
| CYP2C19-inhibitor: | 0.021 | CYP2C19-substrate: | 0.569 |
| CYP2C9-inhibitor: | 0.185 | CYP2C9-substrate: | 0.862 |
| CYP2D6-inhibitor: | 0.009 | CYP2D6-substrate: | 0.731 |
| CYP3A4-inhibitor: | 0.092 | CYP3A4-substrate: | 0.226 |
——————————————————————————————————————————
ADMET: Excretion
| Clearance (CL): | 21.285 | Half-life (T1/2): | 0.236 |
——————————————————————————————————————————
ADMET: Toxicity
| hERG Blockers: | 0.039 | Human Hepatotoxicity (H-HT): | 0.326 |
| Drug-inuced Liver Injury (DILI): | 0.042 | AMES Toxicity: | 0.019 |
| Rat Oral Acute Toxicity: | 0.954 | Maximum Recommended Daily Dose: | 0.826 |
| Skin Sensitization: | 0.048 | Carcinogencity: | 0.185 |
| Eye Corrosion: | 0.003 | Eye Irritation: | 0.009 |
| Respiratory Toxicity: | 0.69 |
——————————————————————————————————————————
*Note: the ADMET properties was calculated by ADMETlab 2.0. Reference: PMID: 33893803.
Similar Compounds*
Compounds similar to EMNPD with top10 similarity:
| Similar NPs | Similar Drugs | ||||||
|---|---|---|---|---|---|---|---|
| NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
| ENC005140 |  |
0.756 | D04DJN |  |
0.505 | ||
| ENC005146 |  |
0.756 | D04RYU |  |
0.450 | ||
| ENC005144 |  |
0.753 | D0U3GL |  |
0.418 | ||
| ENC005142 |  |
0.600 | D0M2QH |  |
0.398 | ||
| ENC005145 |  |
0.596 | D0Q6NZ |  |
0.398 | ||
| ENC005147 |  |
0.580 | D06XMU |  |
0.370 | ||
| ENC002216 |  |
0.465 | D08QKJ |  |
0.364 | ||
| ENC005143 |  |
0.436 | D0Z1XD |  |
0.363 | ||
| ENC002305 |  |
0.379 | D0KR5B |  |
0.355 | ||
| ENC001197 |  |
0.352 | D0L2LS |  |
0.349 | ||